Publications by authors named "Kayoko Mihara"

Claim this Profile
[
[A capability to promote the utilization of human samples for improving the ‍clinical response predictability in the pharmaceutical company].
Risa Okimoto, Takao Fujimura, Kayoko Mihara

Nihon Yakurigaku Zasshi· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect.
Takuma Mihara, Akihiro Noda, Hiroshi Arai, Kayoko Mihara, Akinori Iwashita

J Nucl Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Takuma Mihara, Kayoko Mihara, Junko Yarimizu, Yasuyuki Mitani, Ritsuko Matsuda

J Pharmacol Exp Ther· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Kouji Hattori, Yoshiyuki Kido, Hirofumi Yamamoto, Junya Ishida, Akinori Iwashita, Kayoko Mihara

Bioorg Med Chem Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
Akinori Iwashita, Yuko Muramatsu, Takao Yamazaki, Masakazu Muramoto, Yasuhiro Kita, Kayoko Mihara

J Pharmacol Exp Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.
Junya Ishida, Hirofumi Yamamoto, Yoshiyuki Kido, Kazunori Kamijo, Kenji Murano, Kayoko Mihara

Bioorg Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
Kayoko Mihara, Toshiaki Aoki, Akira Moriguchi, Masashi Maeda, Yasuhisa Furuichi

J Neurotrauma· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors.
Junya Ishida, Kouji Hattori, Hirofumi Yamamoto, Akinori Iwashita, Kayoko Mihara

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419.
Toshio Yamanaka, Mitsuru Ohkubo, Satoru Kuroda, Hideko Nakamura, Fumie Takahashi, Kayoko Mihara

Bioorg Med Chem· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
Akira Moriguchi, Masashi Maeda, Kayoko Mihara, Toshiaki Aoki, Nobuya Matsuoka

J Cereb Blood Flow Metab· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Masashi Maeda, Akira Moriguchi, Kayoko Mihara, Toshiaki Aoki, Hiroyuki Takamatsu

J Cereb Blood Flow Metab· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.
Akinori Iwashita, Kayoko Mihara, Syunji Yamazaki, Shigeru Matsuura, Junya Ishida

J Pharmacol Exp Ther· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
Akira Moriguchi, Kayoko Mihara, Toshiaki Aoki, Masashi Maeda, Nobuteru Tojo

Eur J Pharmacol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Kouji Hattori, Yoshiyuki Kido, Hirofumi Yamamoto, Junya Ishida, Kazunori Kamijo, Kayoko Mihara

J Med Chem· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse.
Hiroyuki Takamatsu, Takeharu Kakiuchi, Akihiro Noda, Hiroshi Uchida, Shingo Nishiyama, Kayoko Mihara

Ann Nucl Med· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Akinori Iwashita, Syunji Yamazaki, Kayoko Mihara, Kouji Hattori, Hirofumi Yamamoto

J Pharmacol Exp Ther· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Akira Moriguchi, Toshiaki Aoki, Kayoko Mihara, Nobuteru Tojo, Nobuya Matsuoka

J Pharmacol Exp Ther· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Yasuko Kato, Yasuhiro Kita, Yoshimi Hirasawa-Taniyama, Mie Nishio, Kayoko Mihara

Eur J Pharmacol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis